Cardiff Oncology, Inc. (CRDF) 10-Year Financial Performance & Capital Metrics

CRDF • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutCardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Show more

Revenue $683K +40.0%
EBITDA -$48M -7.2%
Net Income -$45M -9.6%
EPS (Diluted) -0.95 -2.2%
Gross Margin 100%
EBITDA Margin -7063.98% +23.4%
Operating Margin -7123.13% +23.5%
Net Margin -6651.68% +21.7%
ROE -59.51% -26.4%
ROIC -87.68% -84.0%
Debt/Equity 0.02 -40.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 22.8%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.33%

5Y22.8%

3Y23.91%

TTM-27.29%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.19%

ROCE

10Y Avg-79.32%

5Y Avg-38.85%

3Y Avg-48.37%

Latest-62.79%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	313K	381K	505K	378K	244.63K	366K	359K	386K	488K	683K
Revenue Growth %	0.12%	0.22%	0.33%	-0.25%	-0.35%	0.5%	-0.02%	0.08%	0.26%	0.4%
Cost of Goods Sold+	629K	1.73M	1.81M	597K	0	0	0	0	0	0
COGS % of Revenue	2.01%	4.54%	3.59%	1.58%	-	-	-	-	-	-
Gross Profit+	-316K	-1.35M	-1.31M	-219K	244.63K	366K	359K	386K	488K	683K
Gross Margin %	-1.01%	-3.54%	-2.59%	-0.58%	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-2.19%	-3.27%	0.03%	0.83%	2.12%	0.5%	-0.02%	0.08%	0.26%	0.4%
Operating Expenses+	24.96M	38.01M	22.11M	16.17M	16.92M	19.45M	29.21M	40.29M	45.9M	49.33M
OpEx % of Revenue	79.74%	99.75%	43.79%	42.78%	69.18%	53.15%	81.38%	104.37%	94.06%	72.23%
Selling, General & Admin	14.36M	23M	14.23M	8.01M	5.76M	8.22M	11.84M	13.18M	13.04M	12.48M
SG&A % of Revenue	45.89%	60.36%	28.18%	21.18%	23.55%	22.45%	32.97%	34.15%	26.73%	18.28%
Research & Development	10.59M	15.01M	7.88M	8.16M	11.16M	11.23M	17.38M	27.11M	32.86M	36.85M
R&D % of Revenue	33.85%	39.39%	15.61%	21.6%	45.63%	30.7%	48.4%	70.23%	67.33%	53.96%
Other Operating Expenses	-3K	-145K	-170K	0	0	0	0	0	0	0
Operating Income+	-25.27M	-40.15M	-25.6M	-17.05M	-16.68M	-19.09M	-28.86M	-39.9M	-45.41M	-48.65M
Operating Margin %	-80.75%	-105.37%	-50.69%	-45.11%	-68.18%	-52.15%	-80.38%	-103.37%	-93.06%	-71.23%
Operating Income Growth %	-0.69%	-0.59%	0.36%	0.33%	0.02%	-0.14%	-0.51%	-0.38%	-0.14%	-0.07%
EBITDA+	-24.9M	-39.08M	-24.54M	-16.32M	-16.18M	-18.62M	-28.4M	-39.67M	-45.01M	-48.25M
EBITDA Margin %	-79.54%	-102.56%	-48.6%	-43.17%	-66.16%	-50.87%	-79.12%	-102.76%	-92.24%	-70.64%
EBITDA Growth %	-0.69%	-0.57%	0.37%	0.34%	0.01%	-0.15%	-0.53%	-0.4%	-0.13%	-0.07%
D&A (Non-Cash Add-back)	378.71K	1.07M	1.05M	736.09K	494.23K	466K	451K	236K	398K	404K
EBIT	-25.27M	-37.53M	-23.87M	-16.44M	-16.41M	-19.3M	-28.86M	-39.9M	-45.41M	-48.65M
Net Interest Income+	-1.47M	-1.38M	-886.06K	194.02K	234.17K	88K	264K	1.58M	4.07M	3.26M
Interest Income	57.26K	0	147.88K	219.43K	234.17K	90K	264K	1.58M	4.07M	3.26M
Interest Expense	1.53M	1.38M	1.03M	25.41K	0	2K	0	0	0	0
Other Income/Expense	-2.2M	941.89K	689.05K	-72.45K	264.33K	-221K	564K	1.2M	3.97M	3.22M
Pretax Income+	-27.47M	-39.2M	-24.91M	-16.46M	-16.41M	-19.31M	-28.29M	-38.7M	-41.44M	-45.43M
Pretax Margin %	-87.77%	-102.9%	-49.32%	-43.55%	-67.1%	-52.75%	-78.81%	-100.27%	-84.92%	-66.52%
Income Tax+	1.82M	-296K	716K	617.64K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-27.47M	-39.2M	-24.91M	-16.46M	-16.41M	-19.31M	-28.29M	-38.7M	-41.44M	-45.43M
Net Margin %	-87.77%	-102.9%	-49.32%	-43.55%	-67.1%	-52.75%	-78.81%	-100.27%	-84.92%	-66.52%
Net Income Growth %	-0.92%	-0.43%	0.36%	0.34%	0%	-0.18%	-0.47%	-0.37%	-0.07%	-0.1%
Net Income (Continuing)	-27.47M	-39.2M	-24.91M	-16.46M	-16.41M	-19.31M	-28.29M	-38.7M	-41.44M	-45.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-74.77	-93.22	-51.71	-7.06	-2.70	-1.08	-0.73	-0.89	-0.93	-0.95
EPS Growth %	-0.38%	-0.25%	0.45%	0.86%	0.62%	0.6%	0.32%	-0.22%	-0.04%	-0.02%
EPS (Basic)	-75.49	-93.54	-51.71	-7.06	-2.70	-1.08	-0.73	-0.89	-0.93	-0.95
Diluted Shares Outstanding	367.39K	420.57K	481.67K	2.33M	5.97M	20.88M	39.03M	43.6M	44.68M	47.65M
Basic Shares Outstanding	363.92K	419.1K	481.67K	2.33M	5.97M	20.88M	39.03M	43.6M	44.68M	47.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	68.38M	38.95M	9.47M	12.77M	11.35M	133.36M	146.13M	111.28M	77.41M	95.05M
Cash & Short-Term Investments	67.49M	37.89M	8.23M	11.45M	10.2M	130.98M	140.82M	105.27M	74.82M	91.75M
Cash Only	67.49M	37.89M	8.23M	11.45M	10.2M	130.98M	11.94M	16.35M	21.66M	51.47M
Short-Term Investments	0	0	0	0	0	0	128.88M	88.92M	53.17M	40.28M
Accounts Receivable	98.74K	100.46K	77.09K	167.75K	203.48K	320K	535K	771K	288K	773K
Days Sales Outstanding	115.14	96.24	55.72	161.99	303.6	319.13	543.94	729.05	215.41	413.1
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	5.25M	2.3M	2.54M
Total Non-Current Assets+	3.06M	5M	2.82M	1.41M	1.73M	1.37M	3.42M	4.91M	4.22M	2.14M
Property, Plant & Equipment	2.69M	3.83M	2.43M	1.3M	1.58M	967K	3.18M	3.52M	2.95M	2.07M
Fixed Asset Turnover	0.12x	0.10x	0.21x	0.29x	0.16x	0.38x	0.11x	0.11x	0.17x	0.33x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	374K	1.17M	390K	103K	157.58K	404K	239K	1.39M	1.28M	69K
Total Assets+	71.45M	43.95M	12.29M	14.17M	13.09M	134.73M	149.54M	116.19M	81.64M	97.19M
Asset Turnover	0.00x	0.01x	0.04x	0.03x	0.02x	0.00x	0.00x	0.00x	0.01x	0.01x
Asset Growth %	1.47%	-0.38%	-0.72%	0.15%	-0.08%	9.3%	0.11%	-0.22%	-0.3%	0.19%
Total Current Liabilities+	8.2M	7.8M	3.95M	2.96M	4.78M	6.12M	6.56M	7.81M	10.44M	13.43M
Accounts Payable	1.04M	1.13M	825.24K	664.84K	656.3K	1.37M	1.44M	1.96M	1.97M	4.82M
Days Payables Outstanding	604	238.52	166.32	406.48	-	-	-	-	-	-
Short-Term Debt	5.23M	2.36M	1.33M	0	0	0	0	0	0	0
Deferred Revenue (Current)	589	-611	-11	0	0	0	0	0	0	0
Other Current Liabilities	30.61K	285.25K	651.2K	827.65K	1M	1.56M	1.48M	1.85M	5.05M	2.75M
Current Ratio	8.34x	5.00x	2.40x	4.31x	2.37x	21.79x	22.28x	14.25x	7.41x	7.08x
Quick Ratio	8.34x	5.00x	2.40x	4.31x	2.37x	21.79x	22.28x	14.25x	7.41x	7.08x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	14.54M	16.39M	1.83M	1.12M	993.46K	450K	2.57M	2.04M	1.46M	813K
Long-Term Debt	11.25M	14.18M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	860.96K	9K	2.57M	2.04M	1.46M	813K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.3M	2.21M	1.83M	1.12M	132.5K	441K	0	0	0	0
Total Liabilities	22.75M	24.18M	5.78M	4.09M	5.78M	6.57M	9.13M	9.85M	11.9M	14.24M
Total Debt+	16.47M	16.54M	1.33M	0	1.73M	869K	3.12M	2.71M	2.15M	1.52M
Net Debt	-51.02M	-21.36M	-6.89M	-11.45M	-8.47M	-130.11M	-8.82M	-13.63M	-19.51M	-49.95M
Debt / Equity	0.34x	0.84x	0.20x	-	0.24x	0.01x	0.02x	0.03x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-16.57x	-29.19x	-24.76x	-671.14x	-	-9543.00x	-	-	-	-
Total Equity+	48.7M	19.77M	6.51M	10.08M	7.31M	128.16M	140.42M	106.34M	69.74M	82.95M
Equity Growth %	4.83%	-0.59%	-0.67%	0.55%	-0.27%	16.53%	0.1%	-0.24%	-0.34%	0.19%
Book Value per Share	132.56	47.00	13.51	4.33	1.22	6.14	3.60	2.44	1.56	1.74
Total Shareholders' Equity	48.7M	19.77M	6.51M	10.08M	7.31M	128.16M	140.42M	106.34M	69.74M	82.95M
Common Stock	2.97K	3.07K	5.28K	7.74K	8.31K	4K	4K	4K	4K	7K
Retained Earnings	-108.89M	-148.12M	-173.05M	-192.19M	-208.9M	-231.5M	-259.81M	-298.1M	-339.54M	-384.18M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-854.78K	-10.77K	-2.07M	-2.11M	0	0	-142K	-395K	-67K	34K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-22.12M	-31.04M	-23.28M	-13.2M	-13.27M	-16.32M	-23.04M	-33.82M	-30.89M	-37.69M
Operating CF Margin %	-70.67%	-81.47%	-46.1%	-34.92%	-54.24%	-44.58%	-64.18%	-87.62%	-63.29%	-55.19%
Operating CF Growth %	-0.74%	-0.4%	0.25%	0.43%	-0.01%	-0.23%	-0.41%	-0.47%	0.09%	-0.22%
Net Income	-27.47M	-39.2M	-24.91M	-16.46M	-16.41M	-19.31M	-28.29M	-38.7M	-41.44M	-45.43M
Depreciation & Amortization	378.71K	1.07M	1.25M	859K	494K	466K	451K	236K	398K	404K
Stock-Based Compensation	3.95M	7.5M	4.01M	2.17M	885K	1.76M	3.23M	4.26M	4.51M	4.76M
Deferred Taxes	730.98K	-2.46M	-1.75M	-635K	-28K	0	1.32M	0	0	0
Other Non-Cash Items	434.28K	964K	1.24M	764K	703K	1.42M	2.03M	772K	-921K	-598K
Working Capital Changes	-137.93K	1.09M	-3.13M	98K	1.09M	-654K	-1.79M	-380K	6.57M	3.17M
Change in Receivables	-42.04K	-1.72K	23.36K	19.26M	-35.73M	-117K	-215K	-236K	483K	-484K
Change in Inventory	-361.49M	-2.16B	0	-255.62M	-1.42B	0	0	0	0	0
Change in Payables	361.43M	2.16B	-2.94B	236.48M	1.46B	0	719K	1.35M	2.83M	2.98M
Cash from Investing+	-2.23M	-24.83M	23.96M	23K	-68K	-211K	-131.45M	38.15M	36.2M	13.73M
Capital Expenditures	-2.24M	-823K	-100K	-5.1K	-68K	-211K	-205K	-892K	-582K	-80K
CapEx % of Revenue	7.16%	2.16%	0.2%	0.01%	0.28%	0.58%	0.57%	2.31%	1.19%	0.12%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	7.6K	-823.48M	-101.1M	23K	0	0	-205K	114K	0	0
Cash from Financing+	64.55M	2.3M	-6.38M	16.4M	12.08M	137.31M	35.45M	75K	0	53.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-24.24M	-24.24M	-24.24M	-24.24M	-24.24M	0	-24K	-414K	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	26.49M	24.53M	-866.04K	25.85M	27.5M	25.01M	1.29M	414K	0	373K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-24.36M	-31.86M	-23.38M	-13.21M	-13.34M	-16.53M	-23.25M	-34.71M	-31.47M	-37.77M
FCF Margin %	-77.83%	-83.63%	-46.3%	-34.93%	-54.51%	-45.15%	-64.75%	-89.93%	-64.49%	-55.3%
FCF Growth %	-0.86%	-0.31%	0.27%	0.44%	-0.01%	-0.24%	-0.41%	-0.49%	0.09%	-0.2%
FCF per Share	-66.31	-75.76	-48.54	-5.67	-2.23	-0.79	-0.60	-0.80	-0.70	-0.79
FCF Conversion (FCF/Net Income)	0.81x	0.79x	0.93x	0.80x	0.81x	0.85x	0.81x	0.87x	0.75x	0.83x
Interest Paid	1.06M	1.1M	668.47K	22.48K	0	0	0	0	0	0
Taxes Paid	16.93K	4.56K	800	800	800	1K	1K	2K	1K	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-96.3%	-114.52%	-189.59%	-198.44%	-188.72%	-28.5%	-21.07%	-31.37%	-47.07%	-59.51%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-33.39%	-26.68%	-47.65%	-87.68%
Gross Margin	-100.96%	-354.07%	-258.61%	-57.94%	100%	100%	100%	100%	100%	100%
Net Margin	-8776.68%	-10289.76%	-4932.08%	-4354.76%	-6709.74%	-5275.14%	-7880.5%	-10026.94%	-8492.01%	-6651.68%
Debt / Equity	0.34x	0.84x	0.20x	-	0.24x	0.01x	0.02x	0.03x	0.03x	0.02x
Interest Coverage	-16.57x	-29.19x	-24.76x	-671.14x	-	-9543.00x	-	-	-	-
FCF Conversion	0.81x	0.79x	0.93x	0.80x	0.81x	0.85x	0.81x	0.87x	0.75x	0.83x
Revenue Growth	11.79%	21.73%	32.55%	-25.15%	-35.28%	49.61%	-1.91%	7.52%	26.42%	39.96%

Revenue by Segment

	2019	2020
Royalty	243.14K	365.99K
Royalty Growth	-	50.53%
Service	1.5K	-
Service Growth	-	-

Frequently Asked Questions

Growth & Financials

Cardiff Oncology, Inc. (CRDF) reported $0.5M in revenue for fiscal year 2024. This represents a 94% increase from $0.3M in 2011.

Cardiff Oncology, Inc. (CRDF) grew revenue by 40.0% over the past year. This is strong growth.

Cardiff Oncology, Inc. (CRDF) reported a net loss of $50.4M for fiscal year 2024.

Dividend & Returns

Cardiff Oncology, Inc. (CRDF) has a return on equity (ROE) of -59.5%. Negative ROE indicates the company is unprofitable.

Cardiff Oncology, Inc. (CRDF) had negative free cash flow of $42.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cardiff Oncology, Inc. (CRDF) 10-Year Financial Performance & Capital Metrics

CRDF • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $683K +40.0%
EBITDA -$48M -7.2%
Net Income -$45M -9.6%
EPS (Diluted) -0.95 -2.2%
Gross Margin 100%
EBITDA Margin -7063.98% +23.4%
Operating Margin -7123.13% +23.5%
Net Margin -6651.68% +21.7%
ROE -59.51% -26.4%
ROIC -87.68% -84.0%
Debt/Equity 0.02 -40.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 22.8%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.33%

5Y22.8%

3Y23.91%

TTM-27.29%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.19%

ROCE

10Y Avg-79.32%

5Y Avg-38.85%

3Y Avg-48.37%

Latest-62.79%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	313K	381K	505K	378K	244.63K	366K	359K	386K	488K	683K
Revenue Growth %	0.12%	0.22%	0.33%	-0.25%	-0.35%	0.5%	-0.02%	0.08%	0.26%	0.4%
Cost of Goods Sold+	629K	1.73M	1.81M	597K	0	0	0	0	0	0
COGS % of Revenue	2.01%	4.54%	3.59%	1.58%	-	-	-	-	-	-
Gross Profit+	-316K	-1.35M	-1.31M	-219K	244.63K	366K	359K	386K	488K	683K
Gross Margin %	-1.01%	-3.54%	-2.59%	-0.58%	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-2.19%	-3.27%	0.03%	0.83%	2.12%	0.5%	-0.02%	0.08%	0.26%	0.4%
Operating Expenses+	24.96M	38.01M	22.11M	16.17M	16.92M	19.45M	29.21M	40.29M	45.9M	49.33M
OpEx % of Revenue	79.74%	99.75%	43.79%	42.78%	69.18%	53.15%	81.38%	104.37%	94.06%	72.23%
Selling, General & Admin	14.36M	23M	14.23M	8.01M	5.76M	8.22M	11.84M	13.18M	13.04M	12.48M
SG&A % of Revenue	45.89%	60.36%	28.18%	21.18%	23.55%	22.45%	32.97%	34.15%	26.73%	18.28%
Research & Development	10.59M	15.01M	7.88M	8.16M	11.16M	11.23M	17.38M	27.11M	32.86M	36.85M
R&D % of Revenue	33.85%	39.39%	15.61%	21.6%	45.63%	30.7%	48.4%	70.23%	67.33%	53.96%
Other Operating Expenses	-3K	-145K	-170K	0	0	0	0	0	0	0
Operating Income+	-25.27M	-40.15M	-25.6M	-17.05M	-16.68M	-19.09M	-28.86M	-39.9M	-45.41M	-48.65M
Operating Margin %	-80.75%	-105.37%	-50.69%	-45.11%	-68.18%	-52.15%	-80.38%	-103.37%	-93.06%	-71.23%
Operating Income Growth %	-0.69%	-0.59%	0.36%	0.33%	0.02%	-0.14%	-0.51%	-0.38%	-0.14%	-0.07%
EBITDA+	-24.9M	-39.08M	-24.54M	-16.32M	-16.18M	-18.62M	-28.4M	-39.67M	-45.01M	-48.25M
EBITDA Margin %	-79.54%	-102.56%	-48.6%	-43.17%	-66.16%	-50.87%	-79.12%	-102.76%	-92.24%	-70.64%
EBITDA Growth %	-0.69%	-0.57%	0.37%	0.34%	0.01%	-0.15%	-0.53%	-0.4%	-0.13%	-0.07%
D&A (Non-Cash Add-back)	378.71K	1.07M	1.05M	736.09K	494.23K	466K	451K	236K	398K	404K
EBIT	-25.27M	-37.53M	-23.87M	-16.44M	-16.41M	-19.3M	-28.86M	-39.9M	-45.41M	-48.65M
Net Interest Income+	-1.47M	-1.38M	-886.06K	194.02K	234.17K	88K	264K	1.58M	4.07M	3.26M
Interest Income	57.26K	0	147.88K	219.43K	234.17K	90K	264K	1.58M	4.07M	3.26M
Interest Expense	1.53M	1.38M	1.03M	25.41K	0	2K	0	0	0	0
Other Income/Expense	-2.2M	941.89K	689.05K	-72.45K	264.33K	-221K	564K	1.2M	3.97M	3.22M
Pretax Income+	-27.47M	-39.2M	-24.91M	-16.46M	-16.41M	-19.31M	-28.29M	-38.7M	-41.44M	-45.43M
Pretax Margin %	-87.77%	-102.9%	-49.32%	-43.55%	-67.1%	-52.75%	-78.81%	-100.27%	-84.92%	-66.52%
Income Tax+	1.82M	-296K	716K	617.64K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-27.47M	-39.2M	-24.91M	-16.46M	-16.41M	-19.31M	-28.29M	-38.7M	-41.44M	-45.43M
Net Margin %	-87.77%	-102.9%	-49.32%	-43.55%	-67.1%	-52.75%	-78.81%	-100.27%	-84.92%	-66.52%
Net Income Growth %	-0.92%	-0.43%	0.36%	0.34%	0%	-0.18%	-0.47%	-0.37%	-0.07%	-0.1%
Net Income (Continuing)	-27.47M	-39.2M	-24.91M	-16.46M	-16.41M	-19.31M	-28.29M	-38.7M	-41.44M	-45.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-74.77	-93.22	-51.71	-7.06	-2.70	-1.08	-0.73	-0.89	-0.93	-0.95
EPS Growth %	-0.38%	-0.25%	0.45%	0.86%	0.62%	0.6%	0.32%	-0.22%	-0.04%	-0.02%
EPS (Basic)	-75.49	-93.54	-51.71	-7.06	-2.70	-1.08	-0.73	-0.89	-0.93	-0.95
Diluted Shares Outstanding	367.39K	420.57K	481.67K	2.33M	5.97M	20.88M	39.03M	43.6M	44.68M	47.65M
Basic Shares Outstanding	363.92K	419.1K	481.67K	2.33M	5.97M	20.88M	39.03M	43.6M	44.68M	47.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	68.38M	38.95M	9.47M	12.77M	11.35M	133.36M	146.13M	111.28M	77.41M	95.05M
Cash & Short-Term Investments	67.49M	37.89M	8.23M	11.45M	10.2M	130.98M	140.82M	105.27M	74.82M	91.75M
Cash Only	67.49M	37.89M	8.23M	11.45M	10.2M	130.98M	11.94M	16.35M	21.66M	51.47M
Short-Term Investments	0	0	0	0	0	0	128.88M	88.92M	53.17M	40.28M
Accounts Receivable	98.74K	100.46K	77.09K	167.75K	203.48K	320K	535K	771K	288K	773K
Days Sales Outstanding	115.14	96.24	55.72	161.99	303.6	319.13	543.94	729.05	215.41	413.1
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	5.25M	2.3M	2.54M
Total Non-Current Assets+	3.06M	5M	2.82M	1.41M	1.73M	1.37M	3.42M	4.91M	4.22M	2.14M
Property, Plant & Equipment	2.69M	3.83M	2.43M	1.3M	1.58M	967K	3.18M	3.52M	2.95M	2.07M
Fixed Asset Turnover	0.12x	0.10x	0.21x	0.29x	0.16x	0.38x	0.11x	0.11x	0.17x	0.33x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	374K	1.17M	390K	103K	157.58K	404K	239K	1.39M	1.28M	69K
Total Assets+	71.45M	43.95M	12.29M	14.17M	13.09M	134.73M	149.54M	116.19M	81.64M	97.19M
Asset Turnover	0.00x	0.01x	0.04x	0.03x	0.02x	0.00x	0.00x	0.00x	0.01x	0.01x
Asset Growth %	1.47%	-0.38%	-0.72%	0.15%	-0.08%	9.3%	0.11%	-0.22%	-0.3%	0.19%
Total Current Liabilities+	8.2M	7.8M	3.95M	2.96M	4.78M	6.12M	6.56M	7.81M	10.44M	13.43M
Accounts Payable	1.04M	1.13M	825.24K	664.84K	656.3K	1.37M	1.44M	1.96M	1.97M	4.82M
Days Payables Outstanding	604	238.52	166.32	406.48	-	-	-	-	-	-
Short-Term Debt	5.23M	2.36M	1.33M	0	0	0	0	0	0	0
Deferred Revenue (Current)	589	-611	-11	0	0	0	0	0	0	0
Other Current Liabilities	30.61K	285.25K	651.2K	827.65K	1M	1.56M	1.48M	1.85M	5.05M	2.75M
Current Ratio	8.34x	5.00x	2.40x	4.31x	2.37x	21.79x	22.28x	14.25x	7.41x	7.08x
Quick Ratio	8.34x	5.00x	2.40x	4.31x	2.37x	21.79x	22.28x	14.25x	7.41x	7.08x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	14.54M	16.39M	1.83M	1.12M	993.46K	450K	2.57M	2.04M	1.46M	813K
Long-Term Debt	11.25M	14.18M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	860.96K	9K	2.57M	2.04M	1.46M	813K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.3M	2.21M	1.83M	1.12M	132.5K	441K	0	0	0	0
Total Liabilities	22.75M	24.18M	5.78M	4.09M	5.78M	6.57M	9.13M	9.85M	11.9M	14.24M
Total Debt+	16.47M	16.54M	1.33M	0	1.73M	869K	3.12M	2.71M	2.15M	1.52M
Net Debt	-51.02M	-21.36M	-6.89M	-11.45M	-8.47M	-130.11M	-8.82M	-13.63M	-19.51M	-49.95M
Debt / Equity	0.34x	0.84x	0.20x	-	0.24x	0.01x	0.02x	0.03x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-16.57x	-29.19x	-24.76x	-671.14x	-	-9543.00x	-	-	-	-
Total Equity+	48.7M	19.77M	6.51M	10.08M	7.31M	128.16M	140.42M	106.34M	69.74M	82.95M
Equity Growth %	4.83%	-0.59%	-0.67%	0.55%	-0.27%	16.53%	0.1%	-0.24%	-0.34%	0.19%
Book Value per Share	132.56	47.00	13.51	4.33	1.22	6.14	3.60	2.44	1.56	1.74
Total Shareholders' Equity	48.7M	19.77M	6.51M	10.08M	7.31M	128.16M	140.42M	106.34M	69.74M	82.95M
Common Stock	2.97K	3.07K	5.28K	7.74K	8.31K	4K	4K	4K	4K	7K
Retained Earnings	-108.89M	-148.12M	-173.05M	-192.19M	-208.9M	-231.5M	-259.81M	-298.1M	-339.54M	-384.18M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-854.78K	-10.77K	-2.07M	-2.11M	0	0	-142K	-395K	-67K	34K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-22.12M	-31.04M	-23.28M	-13.2M	-13.27M	-16.32M	-23.04M	-33.82M	-30.89M	-37.69M
Operating CF Margin %	-70.67%	-81.47%	-46.1%	-34.92%	-54.24%	-44.58%	-64.18%	-87.62%	-63.29%	-55.19%
Operating CF Growth %	-0.74%	-0.4%	0.25%	0.43%	-0.01%	-0.23%	-0.41%	-0.47%	0.09%	-0.22%
Net Income	-27.47M	-39.2M	-24.91M	-16.46M	-16.41M	-19.31M	-28.29M	-38.7M	-41.44M	-45.43M
Depreciation & Amortization	378.71K	1.07M	1.25M	859K	494K	466K	451K	236K	398K	404K
Stock-Based Compensation	3.95M	7.5M	4.01M	2.17M	885K	1.76M	3.23M	4.26M	4.51M	4.76M
Deferred Taxes	730.98K	-2.46M	-1.75M	-635K	-28K	0	1.32M	0	0	0
Other Non-Cash Items	434.28K	964K	1.24M	764K	703K	1.42M	2.03M	772K	-921K	-598K
Working Capital Changes	-137.93K	1.09M	-3.13M	98K	1.09M	-654K	-1.79M	-380K	6.57M	3.17M
Change in Receivables	-42.04K	-1.72K	23.36K	19.26M	-35.73M	-117K	-215K	-236K	483K	-484K
Change in Inventory	-361.49M	-2.16B	0	-255.62M	-1.42B	0	0	0	0	0
Change in Payables	361.43M	2.16B	-2.94B	236.48M	1.46B	0	719K	1.35M	2.83M	2.98M
Cash from Investing+	-2.23M	-24.83M	23.96M	23K	-68K	-211K	-131.45M	38.15M	36.2M	13.73M
Capital Expenditures	-2.24M	-823K	-100K	-5.1K	-68K	-211K	-205K	-892K	-582K	-80K
CapEx % of Revenue	7.16%	2.16%	0.2%	0.01%	0.28%	0.58%	0.57%	2.31%	1.19%	0.12%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	7.6K	-823.48M	-101.1M	23K	0	0	-205K	114K	0	0
Cash from Financing+	64.55M	2.3M	-6.38M	16.4M	12.08M	137.31M	35.45M	75K	0	53.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-24.24M	-24.24M	-24.24M	-24.24M	-24.24M	0	-24K	-414K	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	26.49M	24.53M	-866.04K	25.85M	27.5M	25.01M	1.29M	414K	0	373K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-24.36M	-31.86M	-23.38M	-13.21M	-13.34M	-16.53M	-23.25M	-34.71M	-31.47M	-37.77M
FCF Margin %	-77.83%	-83.63%	-46.3%	-34.93%	-54.51%	-45.15%	-64.75%	-89.93%	-64.49%	-55.3%
FCF Growth %	-0.86%	-0.31%	0.27%	0.44%	-0.01%	-0.24%	-0.41%	-0.49%	0.09%	-0.2%
FCF per Share	-66.31	-75.76	-48.54	-5.67	-2.23	-0.79	-0.60	-0.80	-0.70	-0.79
FCF Conversion (FCF/Net Income)	0.81x	0.79x	0.93x	0.80x	0.81x	0.85x	0.81x	0.87x	0.75x	0.83x
Interest Paid	1.06M	1.1M	668.47K	22.48K	0	0	0	0	0	0
Taxes Paid	16.93K	4.56K	800	800	800	1K	1K	2K	1K	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-96.3%	-114.52%	-189.59%	-198.44%	-188.72%	-28.5%	-21.07%	-31.37%	-47.07%	-59.51%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-33.39%	-26.68%	-47.65%	-87.68%
Gross Margin	-100.96%	-354.07%	-258.61%	-57.94%	100%	100%	100%	100%	100%	100%
Net Margin	-8776.68%	-10289.76%	-4932.08%	-4354.76%	-6709.74%	-5275.14%	-7880.5%	-10026.94%	-8492.01%	-6651.68%
Debt / Equity	0.34x	0.84x	0.20x	-	0.24x	0.01x	0.02x	0.03x	0.03x	0.02x
Interest Coverage	-16.57x	-29.19x	-24.76x	-671.14x	-	-9543.00x	-	-	-	-
FCF Conversion	0.81x	0.79x	0.93x	0.80x	0.81x	0.85x	0.81x	0.87x	0.75x	0.83x
Revenue Growth	11.79%	21.73%	32.55%	-25.15%	-35.28%	49.61%	-1.91%	7.52%	26.42%	39.96%

Revenue by Segment

	2019	2020
Royalty	243.14K	365.99K
Royalty Growth	-	50.53%
Service	1.5K	-
Service Growth	-	-

Frequently Asked Questions

Growth & Financials

Cardiff Oncology, Inc. (CRDF) reported $0.5M in revenue for fiscal year 2024. This represents a 94% increase from $0.3M in 2011.

Cardiff Oncology, Inc. (CRDF) grew revenue by 40.0% over the past year. This is strong growth.

Cardiff Oncology, Inc. (CRDF) reported a net loss of $50.4M for fiscal year 2024.

Dividend & Returns

Cardiff Oncology, Inc. (CRDF) has a return on equity (ROE) of -59.5%. Negative ROE indicates the company is unprofitable.

Cardiff Oncology, Inc. (CRDF) had negative free cash flow of $42.3M in fiscal year 2024, likely due to heavy capital investments.